2,194,635 Shares in Precision BioSciences, Inc. $DTIL Bought by Empery Asset Management LP

Empery Asset Management LP purchased a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,194,635 shares of the company’s stock, valued at approximately $9,130,000. Precision BioSciences makes up approximately 8.1% of Empery Asset Management LP’s holdings, making the stock its 5th biggest holding. Empery Asset Management LP owned 9.58% of Precision BioSciences at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after buying an additional 4,025 shares in the last quarter. Lynx1 Capital Management LP grew its holdings in Precision BioSciences by 0.6% during the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after buying an additional 6,545 shares in the last quarter. HBK Sorce Advisory LLC bought a new stake in Precision BioSciences during the fourth quarter worth $38,000. Virtu Financial LLC bought a new stake in Precision BioSciences during the third quarter worth $84,000. Finally, GSA Capital Partners LLP bought a new stake in Precision BioSciences during the third quarter worth $98,000. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Stock Down 6.0%

Shares of NASDAQ:DTIL opened at $6.45 on Thursday. The company has a market capitalization of $166.41 million, a PE ratio of -1.76 and a beta of 1.30. The company has a debt-to-equity ratio of 0.29, a current ratio of 14.02 and a quick ratio of 14.02. The business has a fifty day moving average price of $7.03 and a two-hundred day moving average price of $5.47. Precision BioSciences, Inc. has a 1 year low of $3.53 and a 1 year high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 85.37%. The business had revenue of $10.84 million during the quarter, compared to the consensus estimate of $4.05 million. Analysts forecast that Precision BioSciences, Inc. will post -1.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on DTIL. JonesTrading restated a “buy” rating and issued a $30.00 price objective on shares of Precision BioSciences in a research note on Friday, April 17th. Wall Street Zen upgraded Precision BioSciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a research note on Wednesday, May 27th. Oppenheimer began coverage on Precision BioSciences in a research note on Tuesday. They issued an “outperform” rating and a $20.00 price objective for the company. Finally, Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.25.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.